Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 3/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13681671 | 0.77 | ALDH1A1 (0.44) | MAPTMAPK1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL13042025 | 0.77 | CYP2C9 (0.46) | ITGB3ITGA2BMAPTLMNASMN1; SMN2 | |
| SCHEMBL6467471 | 0.77 | CYP2C9 (0.46) | ITGB3ITGA2BMAPTLMNASMN1; SMN2 | |
| SCHEMBL9911441 | 0.76 | ALDH1A1 (0.50) | MAPTSMN1; SMN2ALDH1A1TSHRKMT2A | |
| SCHEMBL9911440 | 0.76 | ALDH1A1 (0.45) | MAPTLMNAALDH1A1KMT2AKDM4E | |
| SCHEMBL7508743 | 0.75 | ITGB3 (0.42) | ITGB3ITGA2BMAPTLMNATHRB | |
| SCHEMBL23794430 | 0.74 | ALDH1A1 (0.42) | ITGB3ITGA2BMAPTLMNASMN1; SMN2 | |
| SCHEMBL22819453 | 0.74 | ITGB3 (0.41) | ITGB3ITGA2BMAPTLMNAALDH1A1 | |
| SCHEMBL6249964 | 0.72 | SLC22A6 (0.39) | ITGB3ITGA2BMAPTLMNASMN1; SMN2 | |
| SCHEMBL31445041 | 0.72 | ALDH1A1 (0.38) | LMNAALDH1A1AAK1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198458-B2 | Non-nucleoside reverse transcriptase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-12 | — | — | US | disclosed |
| US-20090143370-A1 | Non-nucleoside Reverse Transcriptase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143370-A1 | Non-nucleoside Reverse Transcriptase Inhibitors | RTF1, POLR1A, POLR1E | ITGB3 3481/4885ITGA2B 3181/4885MAPT 2404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.